Call: +7 771 977 66 65, +7 705 421 2277
Sign in or Register
My basket

Astana Biomed Group, an authorized Abcam distributor in Central Asia

Abiomed homepage

  • Categories
    Signal Transduction
    Cancer
    Epigenetics and Nuclear Signaling
    Immunology
    Cell Biology
    Cardiovascular
    Neuroscience
    Tags & Cell Markers
    Kits/ Lysates/ Other
    Developmental Biology
    Microbiology
    Biochemicals
    Secondary antibodies
    Isotype/Loading Controls
    Antibody Arrays
  • About us
  • Partners
  • Contact
    Address

    Saryarka 32, 18, 010000, Astana city, Kazakhstan

    Telephone +7 771 977 66 65, +7 705 421 2277

    Email

    laboratory@ctlab.kz, orders@abiomed.kz

Back to category
Signal Transduction Signaling Pathway Nuclear Signaling NFkB Pathway

c-Rel peptide (ab7557)

Key features and details

  • Suitable for: Blocking

You may also be interested in

Product image
Anti-ZDHHC13 antibody (ab254605)
Product image
Anti-ABIN3 antibody (ab113748)
Product image
Alexa Fluor® 647 Anti-SQSTM1 / p62 antibody [EPR4844] (ab194721)
Product image
Human NFKB2 (NFkB p100/NFKB2) knockout HCT116 cell line (ab266883)

Description

  • Product name

    c-Rel peptide
  • Animal free

    No
  • Nature

    Synthetic

Preparation and Storage

  • c Rel proto oncogene protein
  • Oncogene REL
  • Oncogene REL avian reticuloendotheliosis
  • Proto-oncogene c-Rel
  • REL
  • REL_HUMAN
  • v rel avian reticuloendotheliosis viral oncogene homolog
  • v rel reticuloendotheliosis viral oncogene homolog
  • V rel reticuloendotheliosis viral oncogene homolog (avian)

Images

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

Clear all

Recently viewed products

  •  
  • Product image

    Mouse CD40 ELISA Kit (ab100674)

  •  
  • Product image

    Native human Prethrombin 2 protein (ab62535)

  •  
  • NPR-B peptide (ab150296)

Get resources and offers direct to your inbox Sign up
© 2021 Astana Biomed Group LLP. All rights reserved.